Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Molecular Partners Logo
Molecular Partners Growth Score
91
CB Rank
58921
Heat Score
49
Molecular Partners is a clinical-stage biopharmaceutical company.
Founded
obfuscation
PublicPost-IPO Equity Zürich, Zurich, Switzerland101-250 www.molecularpartners.com
Biotechnology
Medical
Pharmaceutical
Overview

Molecular Partners
Total Funding
obfuscation
Growth Score
91
Heat Score
49

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score91
-3 pts
in past quarter
Heat Score 49
-1 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Molecular Partners

CB Rank
58921
Molecular Partners is a clinical-stage biopharmaceutical company.
Founded
obfuscation
PublicPost-IPO Equity Zürich, Zurich, Switzerland101-250 www.molecularpartners.com
Biotechnology
Medical
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Molecular Partners AG
Operating Status Active
Stock Symbol  SIX:MOLN
Company Type For Profit
Founders  Michael Tobias Stumpp
About the Company
Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics.
Phone Number +41 44 755 77 00
Contact Email info@molecularpartners.com
Predictions & Insights

Growth Insight

See this Growth Insight
Molecular Partners is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Abicipar Pegol
A DARPin therapeutic candidate targeting VEGF-A for treatment of neovascular age-related macular degeneration and diabetic macular edema.
MP0250
A multi-DARPin therapeutic targeting HGF and VEGF pathways for treatment of multiple myeloma and solid tumors.

Research & Development

Molecular Partners is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Molecular Partners Logo
Post-IPO Equity - Molecular Partners
1
obfuscation
HBM Healthcare InvestmentsPost-IPO Equity
obfuscation
Post-IPO Equity - Molecular Partners Logo
Post-IPO Equity - Molecular Partners
1
obfuscation
HBM Healthcare InvestmentsPost-IPO Equity
obfuscation
Post-IPO Equity - Molecular Partners Logo
Post-IPO Equity - Molecular Partners
1
obfuscation
HBM Healthcare InvestmentsPost-IPO Equity
obfuscation
Post-IPO Equity - Molecular Partners Logo
Post-IPO Equity - Molecular Partners
1
obfuscation
HBM Healthcare InvestmentsPost-IPO Equity
obfuscation
Post-IPO Equity - Molecular Partners Logo
Post-IPO Equity - Molecular Partners
1
obfuscation
HBM Healthcare InvestmentsPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Molecular Partners Logo
Post-IPO Equity - Molecular Partners
1
obfuscation
HBM Healthcare InvestmentsPost-IPO Equity
obfuscation
Post-IPO Equity - Molecular Partners Logo
Post-IPO Equity - Molecular Partners
1
obfuscation
HBM Healthcare InvestmentsPost-IPO Equity
obfuscation
Post-IPO Equity - Molecular Partners Logo
Post-IPO Equity - Molecular Partners
1
obfuscation
HBM Healthcare InvestmentsPost-IPO Equity
obfuscation
Post-IPO Equity - Molecular Partners Logo
Post-IPO Equity - Molecular Partners
1
obfuscation
HBM Healthcare InvestmentsPost-IPO Equity
obfuscation
Post-IPO Equity - Molecular Partners Logo
Post-IPO Equity - Molecular Partners
1
obfuscation
HBM Healthcare InvestmentsPost-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 13 Board Members and Advisors 10 Contacts 26

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 30, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 27, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 21, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

2,687
-51.1%
 in past month

IT Spend

$413.9KThis year, Molecular Partners is projected to spend $413.9K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Brand Awareness Logo
Brand Awareness
88
Payroll Software Logo
Payroll Software
86
Snowflake Logo
Snowflake
80

Actively Used Products

17Molecular Partners uses 17 technology products and services including HTML5, Apache Server, and  Adobe Fonts, according to G2 Stack.

Active Website Tech Count

16Molecular Partners is actively using 16 technologies for its website, according to BuiltWith. These include HSTS, IPv6, and  CommonCrawl Top 5m.

Total IP

76The intellectual property of Molecular Partners includes 70 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery. Additionally, Molecular Partners has registered 6 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Molecular Partners's headquarters? Molecular Partners is located in Zürich, Zurich, Switzerland.Who invested in Molecular Partners? Molecular Partners has 11 investors including HBM Healthcare Investments and  Novartis.When was the last funding round for Molecular Partners? Molecular Partners closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Molecular Partners's competitors? Alternatives and possible competitors to Molecular Partners may include Roche, EQT Life Sciences, and  Interius BioTherapeutics.How much funding has Molecular Partners raised to date? Molecular Partners has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(8fe006b 1)
|